Use of 2-deoxy-2-[F-18]-fluoro-D-glucose positron emission tomography to monitor therapeutic response by rhabdomyosarcoma in children: Report of a retrospective case study

被引:21
作者
Peng, Fangyu
Rabkin, Galina
Muzik, Otto
机构
[1] Wayne State Univ, Sch Med, Carman & Ann Adams Dept Pediat, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Dept Radiol, Detroit, MI 48201 USA
[3] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA
关键词
positron emission tomography; 2-deoxy-2-[F-18]-fluoro-D-glucose; rhabdomyosarcoma; pediatrics;
D O I
10.1097/01.rlu.0000222954.38724.be
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: The purpose of this study was to study the use of 2-deoxy-2-[F-18]-fluoro-D-glucose positron emission tomography (F-18 FDG PET) for monitoring therapeutic response by rhabdomyosarcoma (RMSA) in children. Patients and Methods: A retrospective case study was performed by searching a computer database for the patients with RMSA in whom F-18 FDG PET studies were performed pre- and posttreatment. The data of the PET studies from these patients were analyzed in conjunction with clinical treatment and other imaging studies to determine whether interval changes of F-18 FDG uptake by the RMSA reflect response of RMSA to treatment. Results: Four patients with RMSA who received both pretreatment and posttreatment F-18 FDG PET studies were identified from the database and included in this study. A dramatic decrease of F-18 FDG uptake by the tumor was evident in the patients who had a favorable response to the therapy and prolonged remission of the disease. In contrast, persistent abnormal FDG uptake in one patient was associated with early relapse of the RMSA. Conclusions: F-18 FDG PET may be useful for monitoring therapeutic response by RMSA in children, which needs to be verified with a prospective study in a larger patient population.
引用
收藏
页码:394 / 397
页数:4
相关论文
共 15 条
[1]  
Chin Bennett B, 2002, Mol Imaging Biol, V4, P294, DOI 10.1016/S1536-1632(02)00014-8
[2]   Factors that influence treatment decisions in childhood rhabdomyosarcoma [J].
Donaldson, SS ;
Anderson, J .
RADIOLOGY, 1997, 203 (01) :17-22
[3]  
Enzinger FM, 1995, SOFT TISSUE TUMORS, P539
[4]   Molecular imaging of cancer with positron emission tomography [J].
Gambhir, SS .
NATURE REVIEWS CANCER, 2002, 2 (09) :683-693
[5]   IMPORTANCE OF A POSTTHERAPEUTIC RESIDUE IN THE PROGNOSIS OF HEAD AND NECK RHABDOMYOSARCOMA IN CHILDREN [J].
GILLES, R ;
COUANET, D ;
CHEVRET, S ;
SHAPEERO, L ;
FLAMANT, F ;
MEUNIER, M ;
MASSELOT, J .
EUROPEAN JOURNAL OF RADIOLOGY, 1991, 13 (03) :187-191
[6]   Imaging and clinical spectrum of rhabdomyosarcoma in children [J].
Kim, EE ;
Valenzuela, RF ;
Kumar, AJ ;
Raney, RB ;
Eftekari, F .
CLINICAL IMAGING, 2000, 24 (05) :257-262
[7]   MALIGNANT SOFT-TISSUE TUMORS IN A LARGE REFERRAL POPULATION - DISTRIBUTION OF DIAGNOSES BY AGE, SEX, AND LOCATION [J].
KRANSDORF, MJ .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1995, 164 (01) :129-134
[8]   PET/CT in the evaluation of childhood sarcomas [J].
McCarville, MB ;
Christie, R ;
Daw, NC ;
Spunt, SL ;
Kaste, SC .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2005, 184 (04) :1293-1304
[9]  
Pappo Alberto S., 1996, Current Opinion in Oncology, V8, P311
[10]   BIOLOGY AND THERAPY OF PEDIATRIC RHABDOMYOSARCOMA [J].
PAPPO, AS ;
SHAPIRO, DN ;
CRIST, WM ;
MAURER, HM .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :2123-2139